{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:58:54Z","timestamp":1792191534277,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":441,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.modpat.2022.100030","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:45:30Z","timestamp":1673311530000},"page":"100030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma"],"prefix":"10.1016","volume":"36","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Ryum","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Bei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Bialik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis M.","family":"Bodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ladanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Lopardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Offin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie W.","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Travis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie G.","family":"Zauderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6987-2294","authenticated-orcid":false,"given":"Jennifer L.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.modpat.2022.100030_bib1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.modpat.2022.100030_bib2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and future management of malignant mesothelioma: a consensus report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"13","author":"Tsao","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2022.100030_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J\u00a0Cell Physiol"},{"issue":"5","key":"10.1016\/j.modpat.2022.100030_bib4","first-page":"1134","article-title":"Relapse patterns and tailored treatment strategies for malignant pleural mesothelioma recurrence after multimodality therapy","volume":"10","author":"Bellini","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"23","key":"10.1016\/j.modpat.2022.100030_bib5","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2022.100030_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.modpat.2022.100030_bib7","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1158\/1078-0432.CCR-11-2375","article-title":"New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment","volume":"18","author":"Ladanyi","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.modpat.2022.100030_bib8","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.modpat.2022.100030_bib9","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.modpat.2022.100030_bib10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.modpat.2022.100030_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.modpat.2022.100030_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/modpathol.2017.108","article-title":"Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma","volume":"31","author":"Vivero","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2022.100030_bib13","article-title":"Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes","volume":"25","author":"Markowitz","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"11","key":"10.1016\/j.modpat.2022.100030_bib14","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/s41379-020-0588-y","article-title":"Molecular characterization of diffuse malignant peritoneal mesothelioma","volume":"33","author":"Hung","year":"2020","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.modpat.2022.100030_bib15","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/1878-0261.12651","article-title":"Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival","volume":"14","author":"Quetel","year":"2020","journal-title":"Mol Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2022.100030_bib16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2008.08.014","article-title":"Functional inactivation of NF2\/merlin in human mesothelioma","volume":"64","author":"Thurneysen","year":"2009","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.modpat.2022.100030_bib17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.modpat.2022.100030_bib18","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3390\/ijms19040988","article-title":"NF2\/merlin inactivation and potential therapeutic targets in mesothelioma","volume":"19","author":"Sato","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.modpat.2022.100030_bib19","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","article-title":"Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors","volume":"22","author":"Dolly","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.modpat.2022.100030_bib20","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s10637-021-01086-6","article-title":"Phase 1 cohort expansion study of LY3023414, a dual PI3K\/mTOR inhibitor, in patients with advanced mesothelioma","volume":"39","author":"Zauderer","year":"2021","journal-title":"Invest New Drugs"},{"issue":"80","key":"10.1016\/j.modpat.2022.100030_bib21","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1158\/1535-7163.MCT-16-0821","article-title":"Combined inhibition of NEDD8-activating enzyme and mTOR suppresses NF2 loss-driven tumorigenesis","volume":"16","author":"Cooper","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.modpat.2022.100030_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrd4161","article-title":"The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment","volume":"13","author":"Johnson","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.modpat.2022.100030_bib25","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.modpat.2022.100030_bib26","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jtho.2016.12.019","article-title":"BAP1 is altered by copy number loss, mutation, and\/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas","volume":"12","author":"Leblay","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2022.100030_bib27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/path.5551","article-title":"Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma","volume":"253","author":"De Rienzo","year":"2021","journal-title":"J\u00a0Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2022.100030_bib28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"issue":"11","key":"10.1016\/j.modpat.2022.100030_bib29","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","article-title":"BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study","volume":"11","author":"Righi","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"8","key":"10.1016\/j.modpat.2022.100030_bib30","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.modpat.2022.100030_bib31","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/his.14324","article-title":"Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma","volume":"78","author":"Chapel","year":"2021","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.modpat.2022.100030_bib32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41379-019-0310-0","article-title":"MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma","volume":"33","author":"Chapel","year":"2020","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2022.100030_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/his.13872","article-title":"Cytoplasmic MTAP expression loss detected by immunohistochemistry correlates with 9p21 homozygous deletion detected by FISH in pleural effusion cytology of mesothelioma","volume":"75","author":"Hamasaki","year":"2019","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.modpat.2022.100030_bib34","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/dc.24475","article-title":"HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion","volume":"49","author":"Hiroshima","year":"2021","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.modpat.2022.100030_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.lungcan.2018.09.019","article-title":"A\u00a0combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis","volume":"125","author":"Kinoshita","year":"2018","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.modpat.2022.100030_bib36","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.5858\/arpa.2012-0112-RA","article-title":"The separation of benign and malignant mesothelial proliferations","volume":"136","author":"Churg","year":"2012","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"10.1016\/j.modpat.2022.100030_bib37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5858\/arpa.2015-0240-SA","article-title":"New markers for separating benign from malignant mesothelial proliferations: are we there yet?","volume":"140","author":"Churg","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.modpat.2022.100030_bib38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.modpat.2022.100030_bib39","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/PAS.0000000000000616","article-title":"BAP1 immunohistochemistry and p16 FISH in the diagnosis of sarcomatous and desmoplastic mesotheliomas","volume":"40","author":"Hwang","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2022.100030_bib40","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1309\/AJCPP5R2ZJZKCLWN","article-title":"The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations","volume":"135","author":"Monaco","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2022.100030_bib41","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.13123","article-title":"Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma","volume":"70","author":"Shinozaki-Ushiku","year":"2017","journal-title":"Histopathology"},{"issue":"10","key":"10.1016\/j.modpat.2022.100030_bib42","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.modpat.2022.100030_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1309\/AJCPT94JVWIHBKRD","article-title":"Diagnostic usefulness of p16\/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis","volume":"139","author":"Wu","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.modpat.2022.100030_bib44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lungcan.2019.02.004","article-title":"Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia","volume":"130","author":"Yoshimura","year":"2019","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2022.100030_bib45","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.modpat.2022.100030_bib46","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41379-022-01081-z","article-title":"Clinical and molecular validation of BAP1, MTAP, P53, and merlin immunohistochemistry in diagnosis of pleural mesothelioma","volume":"35","author":"Chapel","year":"2022","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2022.100030_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms13131","article-title":"Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets","volume":"7","author":"Chen","year":"2016","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.modpat.2022.100030_bib48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.modpat.2022.100030_bib49","series-title":"WHO Classification of Tumours: Thoracic Tumours","year":"2021"},{"key":"10.1016\/j.modpat.2022.100030_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2022.100030_bib51","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/2159-8290.CD-17-0321","article-title":"Accelerating discovery of functional mutant alleles in cancer","volume":"8","author":"Chang","year":"2018","journal-title":"Cancer Discov"},{"issue":"16","key":"10.1016\/j.modpat.2022.100030_bib52","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.modpat.2022.100030_bib53","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Iacono","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2022.100030_bib54","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5858\/arpa.2015-0508-LE","article-title":"Immunohistochemistry for NF2, LATS1\/2, and YAP\/TAZ fails to separate benign from malignant mesothelial proliferations","volume":"140","author":"Sheffield","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"10.1016\/j.modpat.2022.100030_bib55","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.cell.2006.05.030","article-title":"Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach","volume":"125","author":"Zender","year":"2006","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.modpat.2022.100030_bib56","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/neuonc\/noab114","article-title":"MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma","volume":"23","author":"Bao","year":"2021","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2022.100030_bib57","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s004010050608","article-title":"Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study","volume":"93","author":"Hitotsumatsu","year":"1997","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.modpat.2022.100030_bib58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/PAI.0b013e318289f490","article-title":"The significance of immunohistochemical expression of merlin, Ki-67, and p53 in meningiomas","volume":"22","author":"Pavelin","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"10.1016\/j.modpat.2022.100030_bib59","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2013.08.025","article-title":"Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor merlin\/NF2","volume":"154","author":"Yin","year":"2013","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.modpat.2022.100030_bib64","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.modpat.2022.100030_bib60","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41379-019-0371-0","article-title":"Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma","volume":"33","author":"Brich","year":"2020","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.modpat.2022.100030_bib61","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/cncy.22409","article-title":"Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma","volume":"129","author":"Kinoshita","year":"2021","journal-title":"Cancer Cytopathol"},{"issue":"2","key":"10.1016\/j.modpat.2022.100030_bib62","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41379-019-0309-6","article-title":"Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma","volume":"33","author":"Kinoshita","year":"2020","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.modpat.2022.100030_bib63","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch Pathol Lab Med"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222000308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222000308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:14:44Z","timestamp":1760213684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0893395222000308"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2022.100030","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2022.100030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100030"}}